Compare iShares MSCI Australia ETF (EWA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI Australia ETF trades at $28.62 (market cap $1.17B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 14.4× iShares MSCI Australia ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Medpace Holdings Inc for 14 Days on average.
| EWA | MEDP | |
|---|---|---|
Market Cap | $1.17B | $16.82B |
Volume | 2,121,231 | 223,093 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $630.19 |
52-Week Low | $24.95 | $393.42 |
Typical Hold Time | 61 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.23 with no recent price movement. Technical indicators show a bearish trend with all moving averages signaling sell, while oscillators remain neutral. The ETF faces headwinds from Australian market pressures, including inflation concerns from rising oil prices. Recent institutional activity shows mixed sentiment with Squarepoint Ops reducing its stake by 91.2% while Cetera Investment Advisers increased holdings by 106.1%.
The outlook for EWA remains cautious amid Australian economic pressures, though some analysts see potential for over 20% upside to $34.83 based on commodity exposure benefits. Key risks include persistent inflation, tight monetary policy, and global commodity volatility. Institutional positioning suggests divided sentiment on near-term prospects.
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
